Introduction
Acute cellular rejection (ACR) in heart transplantation remains a sword of Damocles, an impending threat, that cause the burden to the heart transplant recipients worldwide, despite the advances in immunosuppressive strategies. ACR is a T cell-mediated rejection, experienced at least 1 episode by approximately 20-40% of heart transplant recipients in the first post-operative year. 1 The histological hallmark of ACR is the presence of mononuclear cells, predominantly T cells, in the myocardium resulted from the migration of activated T cells from the recipients lymphoid system across vascular endothelium of the heart allograft. 2, 3 Interaction between T cells and endothelial cells are essential in the mechanism of both acute and chronic cellular rejection. 4, 5 The initial event of allograft rejection occurs when recipient T cells are activated by recognizing donor and recipient antigen presenting cells (APC) in a direct and indirect manner. 6 The subsequent events are mainly due to the interaction between endothelial cells and T cells, marked by the increase of graft vascular permeability and local accumulation of macrophages and lymphocytes, all of which lead to endothelial cell death and graft destruction. [7] [8] [9] In a previous study we showed that the levels of miR-142-3p is increased in the circulation during acute cardiac (T cell-mediated) rejection, indicating the potential of miR-142-3p as biomarker for acute rejection post heart transplantation. 10 Relevant to transplant immunity, it has been demonstrated that the expression patterns and levels of several microRNAs are highly regulated in accordance with lymphocyte differentiation and activation. 11, 12 The expression of miR-142-3p is restricted to the hematopoietic cells and has been shown to be highly expressed in T cells and to take a part in CD4 þ CD25 -Treg function. 13, 14 MicroRNAs play an important role in many cardiovascular diseases and biological processes and can be found in tissues as well as in blood and other bodily fluids. Despite the high ribonuclease activity in blood, microRNAs found in circulation are protected from degradation, either by association with proteins such as Ago2, or because of encapsulation in extracellular vesicles. 15 This remarkable stability of circulating microRNAs raises the possibility of using them as diagnostic biomarkers. [16] [17] [18] MicroRNAs are a class of small (19-25 nucleotides long), non-coding RNAs that bind to the 3' UTR of target messenger RNAs (mRNAs), thereby acting as endogenous post-translational gene regulators and has been referred to as dimmer switches of gene expression because of their ability to repress gene expression without completely silencing it. 18, 19 In recent years, the realization that exosomes and other extracellular vesicles have the ability to shuttle functional microRNA between cells has fundamentally shifted the paradigm about gene regulation and intercellular communication. 20, 21 Exosomes are extracellular lipid bilayer structures that range from 30 to 100 nm in diameter. They are membrane-derived vesicles, arise within endosomal compartments called multivesicular bodies, which bud internally to form intraluminal vesicles and release their contents into the extracellular space when they fuse with plasma membrane. Exosomes are able to deliver their cargo, such as functional nucleic acids (microRNA, mRNA and other RNA species), to recipient cells, thereby regulating those cells at a posttranscriptional level. [22] [23] [24] Emerging evidence suggests that exosomes can act as conveyors of immune responses. 25 Immune cell-derived exosomes are released constitutively and their release has been reported earlier in B cells, T cells, dendritic cells and mast cells. 23, [26] [27] [28] Despite the constitutive release of exosomes from T cells, this process is enhanced by T cell activation and has been shown to have a role in immune regulation and implicated in cell to cell communication during immune responses associated with tumours, pathogens and autoimmune diseases. 29 In this study, we investigated the role of miR-142-3p in the intercellular communication between T-cells and endothelium in the setting of cardiac allograft rejection. Our results demonstrate that miR-142-3p was enriched in the exosomes isolated from the serum sample of heart transplant patients with ACR and that those exosomes could modify the expressions of miR-142-3p as well as its target gene, RAB11FIP2, in endothelial cells. We also show that upon T cell activation, miR-142-3p is released to the extracellular compartment, transported by exosomes and received by endothelial cell, and in the recipient cells, miR-142-3p regulates the expression of RAB11FIP2, which causes an increase in endothelial permeability. This miR-142-3p-mediated communication between T cells and endothelial cells broadens our understanding about the functional role of circulating miR-142-3p in the molecular mechanism of T cell-mediated graft rejection.
Methods

MicroRNA profiling assay of serum exosomes from heart transplant patients
The 10 heart transplant patients included in this study were part of the Biomarkers in Transplantation (BiT) Canada-wide Trial conducted by Prevention of Organ Failure (PROOF) centre, Vancouver, Canada. Research ethics committee has approved the study and all subjects gave their informed consent in accordance to US National Institutes of Health guidelines and the principles outlined in Declaration of Helsinki. The patients consist of five heart transplant patients with acute cellular rejection (ACR) and five non-rejection (NR) patients as the control group. ACR and NR was defined according to International Society of Heart and Lung Transplantation (ISHLT) 2005 classification.
A qPCR-based microRNA-profiling assay for 175 microRNAs known to be present in human serum was performed using Serum/Plasma Focus Human microRNA PCR panels (Exiqon) according to the manufacturer's instructions. Quantitative RT-PCR was performed using a StepOnePlus Real-Time PCR System (Applied Biosystems). Data analysis was performed using GenEx qPCR Data Analysis Software (MultiD). MiR-451a was used as the reference microRNA in this population as has been described earlier. 10 A heatmap was generated based on the raw miRNA expression values before normalization and 2-way hierarchial clustering was performed.
Isolation of T Cells
Human peripheral blood from six healthy volunteer donors was collected in BD Vaccutainer venous blood collection tubes. Informed consents of the donors were obtained prior to the inclusion of the donors in the study and approved by Lund University Ethics Committee in accordance to US National Institutes of Health guidelines and the principles outlined in Declaration of Helsinki. To obtain the buffy coats, the collected blood was centrifuged at 400 G for 20 min in room temperature. supplemented with 10% foetal bovine serum (FBS) and 1% Penicillin/ Streptomycin.
Cells activation and exosome isolation
To activate the T cells, two of T cells activation approaches were used. First, polyclonal activation method using Phytohemagglutinin (PHA) and IL-2, 30 where 2% v/v of PHA and 10 ng/ul of IL-2 were added to the T cell culture medium, was performed. Second, T cells were activated using beads coated with anti-CD3 and anti-CD28 to stimulate T cells in a manner that mimics stimulation by antigen-presenting cells (APC), as has been described before, 31 using Dynabeads CD3/CD28 Human TActivator (Life Technologies). To isolate exosomes, the T cell culture medium was collected and centrifuged for 10 min at 300 G to remove cell debris, followed by subsequent ultracentrifugation at 200.000 G for 1 h. All centrifugation was performed at 4C. Both exosomes and culture medium without exosomes were collected.
Stimulation of endothelial cells
Human Umbilical Vein Endothelial Cells (HUVECs, Thermo Fischer Scientific) were cultured in Medium 200 (Thermo Fischer Scientific) supplemented with low serum growth supplement (LSGS). HUVECs were stimulated with exosomes isolated from either serum samples from heart transplant patients with ACR or activated T cells. As control for the T cell exosomes stimulation, cells were cultured with RPMI 1640 þ FBS þ Penicillin/Streptomycin and also ultracentrifuged culture media without exosomes for 24 h. Serum exosomes from non-rejection heart transplant patients were used as control for the serum exosomes stimulation.
RNA Isolation from stimulated endothelial cells
Cultured HUVEC cells were lysed in 700 ll Qiazol and subsequent RNA isolation was performed using microRNeasy mini kit (Qiagen) according to the manufacturer's instructions. 
qRT-PCR
Western blot analysis
Cells were washed twice with PBS and lysed in Laemmli sample buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% Glycerol). After protein determination using BCA protein assay kit (Thermo Fisher Scientific), bromophenol blue and ß-mercaptoethanol were added to the samples. Equal amounts of protein (7 lg) were loaded in each lane of Bio-Rad TGX 4-15% Criteron gels. Proteins were detected using commercially available primary antibodies: RAB11FIP2 (1:1000, Abcam, ab76892), cofilin (1:1000, Abcam, ab124979). Secondary rabbit antibody was used (#7074p2, 1:5000, Cell Signalling). Bands were visualized using ECL (Pierce West Femto) and images were acquired using the Odyssey Fc Imager (LI-COR Biosciences).
3'-UTR Target Plasmid Reporter Assay
For validation of predicted mRNA targets, miTarget miRNA 3'UTR Target Clones (Genecopoeia) were used. The expression clones were based on pEZX-MT51 vector containing dual reporter genes, Gaussia luciferase (GLuc) and Secreted Alkaline Phosphatase (SEAP). SEAP serves as an internal control for normalization of transfection efficiency and cell viability. A miTarget miRNA 3'UTR Target clone containing either nucleotides 1-2113 or 2018-4115 of the RAB11FIP2 3'-UTR was co-transfected with either 50 nM of precursor miR-142 (Life Technologies) or scrambled pre-miRNA as a negative control in HUVECs. The miR-142-3p target site at position 2642-2648 of the RAB11FIP2 3' UTR was deleted using the Phusion Site-Directed Mutagenesis kit (Thermo Fisher) according to the manufacturer's instructions, with forward primer 5'-TCTTACGTACGGGTTGATGGT TGTTCTC-3' and reverse primer 5'-AACCCGTACGTAAGAAAT TTCGTATTTTCGTTTTTATT-3'. Deletion of the miR-142-3p target sequence was confirmed with Sanger sequencing. An empty miTarget vector was transfected as a control. The transfection in HUVECs was performed using Nucleofector device and its corresponding HUVEC Nucleofector Kit (Lonza). SEAP and GLuc activity were measured 72 hours after transfection using Secrete-Pair Dual Luminescence Assay Kit (Genecopoeia) on a Glomax 20/20 Luminometer (Promega). Results were expressed as the ratio of GLuc and SEAP.
Blockage of transcription in endothelial cells
HUVECs were treated with 1 lg/mL of Actinomycin D (Sigma) for 30 minutes and washed with PBS after the treatment. The cells were subsequently maintained in culture for 24 h in the presence or absence of T cell exosomes. MiR-142-3p transfer between T cell exosomes and endothelial cells was analysed by evaluating miR-142-3p expression in endothelial cells.
Vascular Permeability Assay
HUVECs ( 
size; Corning). After siRNA-mediated knockdown of RAB11FIP2, 1 mg/ ml FITC dextran (MW 70 kDA, Sigma) was added to the upper compartment of transwell plate. To the lower compartment, 600 ll of Medium 200 was added. The medium from lower compartment was collected at different time points and the amount of passed FITC dextran to the lower compartment was measured (VICTOR 3TM , Perkin Elmer).
Exosome transfer in miR-142-3p inhibited endothelial cells
HUVECs were cultured to approximately 80% confluency in 24-well cell culture plate or fibronectin-coated insert of 24-well transwell plate (0,4 lm pore size; Corning). Cells were transfected with 50 nM of miR-142 inhibitor (Life Technologies) according to the manufacturer's instructions. Scrambled pre-microRNA was used as a negative control. After 72 h incubation, cells were treated with T cell exosomes for 24 h and subsequently harvested for qPCR or vascular permeability assay analysis.
Statistical Analysis
Data are presented as means ± standard errors of the means (SEM), unless indicate otherwise. Bonferroni correction was used to correct for multiplicity in the microRNA profiling assay. Comparisons between experimental group was performed with Mann-Whitney U test for comparison between two groups, Kruskal-Wallis followed by Dunn's test for multiple comparison comparing mean of each group to the mean of control group or for multiple comparison across the mean of each group and two-way ANOVA followed by Turkey's post-analysis for evaluating parameter changes between different groups over time. P-values are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Results
MiR-142-3p is among the microRNAs enriched in the exosomes of heart transplant patients with ACR Although exosomal microRNA has been shown to play important roles in various aspects of inflammation, the exosomal microRNA content in the context of acute cellular rejection has not been extensively analysed. Therefore, we performed a qPCR-based microRNA profiling on exosomes from heart transplant patients with and without ACR (n = 5 in each group, Table 1 ). The profiling panel consisted of 175 microRNAs with high abundance in the circulation (a list of all microRNAs on the panel can be found in see Supplementary material online, Table S1 ). Figure 1A shows the complete miRNA profile for each patient. Analysis of differentially expressed miRNAs showed that miR-142-3p, miR-92a-3p miR-339-3p and miR-21-5p, were enriched in exosomes from patients with ACR compared to non-rejection controls (fold change >1.5, P < 0.05, Figure 1B) . Following correction for multiple comparisons, miR-142-3p, miR-92a-3p miR-339-3p remained statistically significant ( Figure  1C) . No microRNAs were significantly decreased or depleted in ACR exosomes. We chose to focus the remainder of the study on the role of miR-142-3p. There were several reasons for this: (1) it is a hematopoietic-tissue specific microRNA, (2) its expression increases in the circulation of heart transplant recipient with ACR 10 and (3) it has been shown to be involved in promoting tolerance in solid organ transplantation. 32 
MiR-142-3p is expressed in primary mononuclear cell subtypes and released from activated T cells via exosomes
We hypothesized that exosomal miR-142-3p in the circulation of patients with acute rejection stems from activated leucocytes. To test this, we first treated peripheral blood mononuclear cells (PBMC) of healthy donors with phytohemagglutinin (PHA) and interleukin 2 (IL-2) and analysed the levels of miR-142-3p in the medium serially. We could detect a 5-fold increase in miR-142-3p in the medium 6 hours after activation compared to baseline (P < 0.05, see Supplementary material online, Figure S1 ), indicating that activated mononuclear cells could constitute a source of circulating miR-142-3p.
To investigate the cellular source of released miR-142-3p, we first analysed the expression of miR-142-3p in leucocyte subpopulations of healthy donors and showed that it presents in monocytes, monocytederived macrophages, T cells and B cells, with the highest expression found in monocytes and T cells (Figure 2A) . We could confirm the release of miR-142-3p from T cells after stimulation both with PHA/IL-2 and anti-CD3/CD28. Moreover, there was a decrease in intracellular levels of miR-142-3p after both treatments. Despite the similarities in the extracellular level and intracellular expression patterns of both T cells stimulation methods, we observed that the stimulation of T cells using PHA/IL-2 method resulted in the higher increase of extracellular miR-142-3p level ( Figure 2B ). Based on these findings, and considering the prominent role of T cells in the orchestration of acute graft rejection, 8 we chose to focus the rest of the study on T cell-mediated miR-142-3p release.
As it has been shown in several studies that microRNA-containing exosomes are released into the extracellular compartment during physiological and pathological conditions, 23, 33 we assessed whether miR- Exosomal miRNA in allograft rejection of activated T cells. The level of miR-142-3p increased significantly in the exosome fraction six hours after T cell activation, but not in the supernatant fraction ( Figure 2C) . Moreover, inhibition of exosome biogenesis by pre-treating T cells with Brefeldin before activation caused a complete inhibition of miR-142-3p release, further confirming that the released miR-142-3p is contained within exosomes ( Figure 2D) . As a positive control for the miR-142-3p selective enrichment in T cell exosomes, miR-142-5p expression was also evaluated (see Supplementary material online, Figure S2 ).
Uptake of exosomal miR-142-3p from activated T cells by endothelial cells
Recent evidence has shown that microRNA transport is a novel mode of cell communication and that genetic exchange of microRNA in human cells, accomplished through exosome-mediated transfer, can regulate the recipient's cells at a post-transcriptional level. 21, 22, 33 Endothelial cells play a central role in immune responses and are crucial to the development of inflammatory diseases. 34 We hypothesized that the miR-142-3p-containing exosomes released by activated T-cells might be taken up by endothelial cells, and possibly have a role in the pathogenesis of T cell-mediated graft rejection.
To investigate whether endothelial cells take up miR-142-3p, HUVECs were incubated for 24 hours with supernatant from activated T cells, pure exosomes isolated from activated T cells or exosomedepleted supernatant. The expression of miR-142-3p was increased in HUVECs treated with supernatant and isolated exosomes, but not with exosome-depleted supernatant ( Figure 3A) . To confirm that the increased level of miR-142-3p in HUVECs was due to transfer of microRNA, and not increased endogenous expression, the expression of primary miR-142 (pri-miR-142) was also assessed in the stimulated HUVECs. No difference in pri-miR-142 could be detected between treatment groups, indicating that the increased miR-142-3p was due to uptake ( Figure 3B ). To provide a second line evidence of miR-142-3p transfer to endothelial cells, the transcription inhibition of endothelial cells was performed and the results showed that miR-142-3p expression is increased in the cells treated with T cell exosomes after the transcription blockage ( Figure 3C) . Moreover, in line with in vitro results, treatment of endothelial cells with exosomes from the serum of heart transplant patients with ACR resulted in increased of miR-142-3p level in endothelial cells ( Figure 3D ).
RAB11FIP2 expression is decreased in endothelial cells by uptake of miR-142-3p
To gain insight into the effect of exosome-mediated uptake of miR-142-3p in HUVECs on a transcriptome-wide level, we performed microarray analysis on cells treated with whole T cell supernatant and cells treated with exosome-depleted supernatant. To identify genes that were affected by exosome-uptake, we compared differentially expressed genes in cells treated with whole supernatant to cells treated with exosomedepleted supernatant and selected genes that were unique to the former group (i.e. "exosome-regulated genes"). Considering that an increase in miR-142-3p would result in down-regulation of its corresponding target genes, we identified exosome-regulated genes that were decreased >1.5-fold (n = 344 with FDR < 5%) on the microarray. Among those genes we aimed to find genes with a high probability of being true miR-142-3p targets by comparing them with in silico predicted target genes. Using five different target prediction tools (miRanda, miRDB, miRWalk, RNA22 and TargetScan) we identified 4165 potential miR-142-3p target genes. Of these, the 1169 genes that were predicted by > _ 3 prediction tools were chosen for further analysis. Among these genes, 37 overlapped with the exosome-regulated genes above (see Supplementary material online, Table S2 ). This represents a statistically significant enrichment of predicted miR-142-3p targets in the list of exosome-regulated genes, compared to the transcriptome as a whole (two-tailed binomial test, P < 0.001). A literature search was conducted in order to find candidate genes with potential importance for vascular biology, inflammation or graft rejection. Seeing as RAB11 and RAB11FIP2 were very recently implicated in the regulation of endothelial barrier function, 35 we chose to focus the rest of the study on RAB11FIP2. An overview of the analysis pipeline is depicted in Figure 4A . Consistent with the results of the microarray, qPCR analysis revealed a statistically significant decrease in RAB11FIP2 expression in HUVECs treated with T-cell exosomes, but not in cells treated with exosomedepleted supernatant ( Figure 4B) . As positive control, several miR-142-3p predicted target genes (ARL1, TLX1, KIF5B, ENAH, AKAP11 and LRP8) were also analysed using the same treatment and the result showed that ARL1, TLX1, KIF5B and ENAH expressions were also down-regulated with the presence of T cell exosomes (see Supplementary material online, Figure S3) .
To investigate the physiological effect of exosome transfer in endothelial cell in the setting of cardiac allograft rejection, HUVECs were treated with exosomes extracted from serum samples of heart transpant patients. RAB11FIP2 expression in HUVECs was down-regulated when treated with exosomes from ACR patients compared to non-rejection controls, suggesting the transfer of miR-142-3p from the serum samples of ACR patients and subsequent interaction of miR-142-3p and its target, RAB11FIP2 ( Figure 4C) .
To confirm RAB11FIP2 as a target for miR-142-3p in endothelial cells, HUVECs were transfected with pre-and anti-miR-142. Overexpression of miR-142-3p was confirmed in HUVECs treated with pre-miR-142, but successful knock down of miR-142-3p could not be achieved, probably due to the very low endogenous expression of miR-142 (see Supplementary material online, Figure S4) . As expected of a true miR-142-3p target, RAB11FIP2 expression was significantly decreased both on the mRNA and protein level in cells transfected with pre-miR-142 compared to cells transfected with scrambled control pre-miRNA ( Figure 5A and B) .
According to TargetScan, there are two predicted miR-142-3p target sites in the 3' UTR of RAB11FIP2, one at nucleotide position 425-431 (Target site I) and the other at nucleotide position 2642-2648 (Target site II, Figure 5C ). To confirm the interaction of miR-142-3p and RAB11FIP2 mRNA, two reporter plasmids each containing one of the predicted target sites was transfected together with pre-miR-142 precursor microRNA in HUVECs. The reporter signal (Gaussia luciferase) from the plasmid containing Target Site II, but not from Target Site I, was significantly quenched by overexpression of miR-142-3p, indicating that Target Site II is a functional target of miR-142-3p. As a control experiment, Target Site II was deleted from the reporter plasmid using sitedirected mutagenesis. The signal from the mutated RAB11FIP2 plasmid was unaffected by miR-142-3p overexpression, confirming that this particular target sequence is necessary for miR-142-3p binding to the RAB11FIP2 3'-UTR( Figure 5C ).
Knockdown of RAB11FIP2 expression in endothelial cells resulted in increase of vascular permeability
In T cell-mediated cellular rejection, the increase of vascular permeability results in accumulation of lymphocytes and macrophages, which leads to tissue ischaemia and graft destruction. RAB11FIP2 has been shown to play a role in cell polarity, 36 and it interacts with RAB11, a regulator of vascular endothelial barrier integrity and function. 35 We hypothesized that the decrease in RAB11FIP2 expression caused by endothelial uptake of miR-142-3p would lead to increased endothelial permeability. We perfomed siRNA-mediated knock down of RAB11FIP2 in HUVECs and evaluated endothelial permeability in a transwell assay. Successful knock down of RAB11FIP2 was confirmed in HUVECs 72 h post-transfection (see Supplementary material online, figure S5 ). The permeability of confluent HUVECs to FITC-Dextran increased significantly in cells treated with RAB11FIP2 siRNA, indicating that RAB11FIP2 is required for endothelial barrier function. ( Figure 6A ). Treating HUVECs with T cell exosomes resulted in a similar increase in vascular permeability ( Figure 6B) . In order to confirm that this effect was mediated by miR-142-3p, we pre-treated HUVECs with anti-miR-142 before addition of exosomes.
Inhibiting transferred miR-142-3p in this manner reversed the effect of exosome-treatment on HUVEC permeability ( Figure 6B) . A parallel rescue of RAB11FIP2 expression could be seen in HUVECs pre-treated with anti-miR-142. ( Figure 6C ). Taken together, these findings suggest that RAB11FIP2 expression and endothelial cell permeability is regulated by miR-142-3p uptake.
Discussion
A newly identified way of cell-to-cell communication involves intercellular transfer of exosomes carrying functional microRNA, which can be taken up by recipient cells. A vast array of cell types has been demonstrated to release exosomes, the most studied extracellular vesicle of endocytic origin, which can be detected in vivo from the bodily fluid 37 and in the culture supernatants of in vitro cultured cells. 25, [38] [39] [40] We have shown in this study that miR-142-3p-containing exosomes were released to the extracellular milieu upon T cell-mediated rejection episode of heart transplantation, as well as in vitro activation of human T cells purified from the peripheral blood. It has been reported earlier that human T cells from peripheral blood as well as human T lymphocyte cell lines secrete exosomes in a constitutive manner and that the secretion of T cell-derived exosomes is enhanced by TCR triggering and T cell activation. 28 , 41 We observed in this study that miR-142-3p-containing exosomes were gradually increased in the supernatant as early as 3 h post T cell activation and reached its peak after 6 h. Whether the exosomes released in such acute stimulation has the same intracellular origin as the spontaneously secreted exosomes is still unknown, to our knowledge no study has ever extensively shown a side-by-side comparison of steady state and activated T cells-derived exosomes. On the other hand, there have been some studies showing microRNA to be part of the cargo shuttled by T cell-derived exosomes in studies on Jurkat T cell line 42 and other T cell clones. 43 So, we used this strategy to understand the involvement of miR-142-3p in the molecular mechanism of acute cellular rejection orchestrated by T cells and its interaction with endothelial cells. Figure 4 RAB11FIP2 is an exosome-regulated gene targeted by miR-142-3p (A) Overview of bioinformatics analysis. RAB11FIP2 expression in endothelial cells affected by the treatment of (B) T cells exosomes (n = 12) and (C) exosomes from the serum of heart transplant patients with and without rejection (NR = 5; ACR = 5). All data are means þ/-SEM. Statistical analysis was performed with Mann-Whitney U test for two group's comparison and KruskalWallis followed by Dunn's post-analysis for multiple group comparisons. *P < 0.05: **P < 0.01; ***P < 0.001.
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Aberrant expression of microRNAs can contribute to pathological conditions of the immune system and have also been demonstrated to be useful as diagnostic and prognostic indicators of disease severity associated with the immune status of the individual. 44 Relevant to transplant immunity, there has been mounting evidence showing alterations of the microRNA profile in circulating blood in the setting of graft rejections in different organs. [45] [46] [47] The ability of microRNAs to specifically target key cellular pathways, combined with the fact that immune cell-derived exosomes can be modified to prolong cardiac allograft survival in vivo in a mouse cardiac transplantation model, 48 might raise the possibility to use this strategy for the development of novel therapies. Target Site II) . Right, dual luciferase assays were performed to evaluate the interaction between miR-142-3p and its predicted target sequences in the RAB11FIP2 3'UTR using luciferase reporter constructs. A plasmid were Target Site II was deleted (RAB11FIP2-mutant) was used as control. Overexpression of miR-142 in the endothelial cells caused quenching of the signal from the reporter vector containing Target Site II (n = 6) but not Target Site I. Deletion of Target Site II rendered the reporter vector unresponsive to miR-142 overexpression. All data are mean þ/-SEM. Statistical analysis was performed with Man-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001. Despite several observations that suggest the involvement of miR-142-3p in the inflammatory response of solid organ transplantations 32, 49, 50 and that miR-142-3p has a high serological level during acute cellular cardiac rejection, 10 which is a T-cell mediated rejection, the exact role of miR-142-3p in mediating inflammation in transplanted organ remained elusive. In this study we provide new insight on the role of miR-142-3p in T cell-mediated inflammation by demonstrating that miR-142-3p is enriched in the exosomes isolated from heart transplant patients with ACR, can be transferred to the endothelial cells and is able to subsequently affect endothelial cell permeability via its target gene, RAB11FIP2. We also demonstrated that T cells are one likely source of exosomal miR-142-3p and that T-cell derived exosomes can transfer miR-142-3p to endothelial cells and regulate the expression of RAB11FIP2. RAB11-family interacting proteins (RAB11FIPs) comprise 5 family members (FIP1-5) in humans, all of which interact with RAB11. The most recent study about endothelial barrier function reveals the important role of RAB11a, a RAB11 subfamily member, in vascular endothelial barrier integrity, 35 by showing that RAB11a interaction with vascular endothelial (VE)-cadherin through Rab11a-binding protein FIP2 is essential to maintain and restore vascular endothelial integrity, and that the knockdown of RAB11a in pulmonary microvessel cells causes increased vascular leakage in mice. RAB11FIP2 was suggested by our microarray data analysis, supported by several bioinformatic microRNA target prediction tools, to be a target gene for miR-142-3p. We confirmed this finding by demonstrating the interaction between miR-142-3p and one of two predicted target sites in the 3'UTR of RAB11FIP2 in endothelial cells. This result reinforces our hypothesis that functional miR-142-3p released by T cells impairs endothelial cell function by targeting gene expression in recipient cells. Vascular endothelial cells take part in the mechanism of allograft rejection by advancing the recruitment and the activation of alloreactive T cells. 4, 9 Endothelial cells and T cells have been implicated in graft rejection due to the unique location of endothelial cells of donor organ that lays at the interface between recipient's circulation, ergo recipient's immune cells, and the allograft. This is supported by histopathologic findings in the allograft during acute cellular rejection, which is characterized by the accumulation of inflammatory infiltrates, mainly comprised of T cells. 51 The accumulation of immune cells in the allograft is initiated by the inflammatory reaction of endothelial cells, which results in an increase in vascular endothelial permeability and leads to endothelial cell death and graft destruction. Parameter changes between different groups over time were evaluated by two-way ANOVA followed by Turkey's post-analysis for multiple comparison.
